Skip to main content
INTI
OTC Life Sciences

Inhibitor Therapeutics Reaffirms Going Concern With Just $146,193 Cash; Insiders Extend $600K Lifeline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.08
Mkt Cap
$13.903M
52W Low
$0.034
52W High
$0.124
52W Position info
137% above low
Off High info
35% below high
Rel. Volume info
5.7× avg
Market data snapshot near publication time

INTI has more than doubled off its 52-week low of $0.034 on elevated volume (5.7× avg).

Summary

Inhibitor Therapeutics reported $146,193 of cash at September 30, 2026 and reaffirmed substantial doubt about its ability to continue as a going concern, with only a $600,000 insider-funded credit line as new liquidity.


Key Events · Legal and Risk Events · INTI

  • Going Concern Doubt Reaffirmed

    Management projects insufficient liquidity to sustain operations for one year from the filing date and concludes its plans do not currently alleviate substantial doubt.

  • Cash Falls to $146,193

    Cash and equivalents dropped from $2,375,493 at December 31, 2025 to $146,193 at September 30, 2026, after a $1,890,738 nine-month net loss and $2,229,300 of negative operating cash flow.

  • Insider Credit Lines of $600,000

    On November 9, 2026 the company signed lines of credit with CEO Hopkins Capital Group ($300,000), director and 10% owner Ronald Osman ($150,000) and 10% owner TPB 2012 ($150,000) at 4.67%, maturing November 9, 2029; $300,000 was drawn in November 2026.

  • $3.0M Judgment Still Uncollected

    The February 19, 2026 securities purchase agreement for 12 million shares and a 7 million-share warrant at $0.35 remains unfunded; a $3.0 million default judgment was entered August 3, 2026 and the company is pursuing execution, with no receivable recorded.


Analysis · INTI · Life Sciences

With $146,193 of cash at September's end, a $1.9 million nine-month operating loss and $2.2 million of negative operating cash flow, management states plainly that it cannot fund operations for the next twelve months. The only new money is a $600,000 related-party line of credit signed November 9, 2026 by the CEO, a director and a 10% holder at 4.67% — $300,000 of which has been drawn — and the filing itself says that is not enough to remove the going concern doubt. Because the $3.0 million February 2026 securities purchase agreement remains unfunded despite an August 3, 2026 default judgment, the balance sheet now depends on collecting a judgment from an investor who has already refused to pay. For existing holders, further equity issuance is the only realistic path to keep the itraconazole program alive.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INTI was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.9M. The 52-week trading range was $0.03 to $0.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INTI - Latest Insights

INTI
Aug 17, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.081658
Real-time Price: $0.080 info
Change: -$0.001658 (-2%) info
Market Cap: $13.903M info
INTI
Aug 14, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.081658
Real-time Price: $0.080 info
Change: -$0.001658 (-2%) info
Market Cap: $13.903M info
INTI
May 15, 2026, 3:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.083
Real-time Price: $0.080 info
Change: -$0.0030 (-4%) info
Market Cap: $13.903M info
INTI
Apr 01, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.10875
Real-time Price: $0.080 info
Change: -$0.02875 (-26%) info
Market Cap: $13.903M info
INTI
Apr 01, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.10875
Real-time Price: $0.080 info
Change: -$0.02875 (-26%) info
Market Cap: $13.903M info